Hello everyone, I am new to this board. I am an African American female looking for other African Americans who have treated or are currently treating. I would like to know their experiences with treatment and if they are treating with the new meds are they responding. I am a Genotype 1a and looking to treat with Victrelis in January or February.
Hi Hopeful. Thanks for asking this question. Yes! I am in the same boat. African American female. Hep C, Gen 1, beginning VL - 10,700,000. Started September 1st with 4 week lead-in of SOCs. VL dropped to - 329,000. Added Victrelis at week 5. Will go for labs again October 25th and hopefully have 8 week results (so, 4 weeks on VIC + SOCs) to share on Halloween.
Giving you a bump up.
Anybody else out there? Either pre, post or currently treating?? We have factors that make this more difficult but there is a lot of hope with triple therapy, and perhaps, even more with the all orals (but no way of knowing for sure how soon those will be an option, other than in Clinical Trials).
Hello, just wanted to welcome you Hopeful. I am not AA but I enjoy seeing diversity develop on this list. We also see people from other countries and cultures which really contributes to the on line experience I think. Hope you and I and Bee will become HepC free soon!
Welcome! Glad to have you aboard. Sorry you have hep C but now is the best time ever to successfully treat the virus.
Here is the data from the the clinical trials for Victrelis (formerly called Boceprevir) regarding SVR (cure) rates for African-Americans who have never been treated before and and treatment-experienced patients, not including null responders to previous treatment.
"Boceprevir was evaluated for genotype 1 HCV infection in randomized, double-blind phase III trials of treatment-naive patients (SPRINT-2) and treatment-experienced patients, not including null responders to pegIFN/RBV (RESPOND-2). Based on the theoretical concept that reducing viral levels before the administration of the DAA agent might protect against resistance, boceprevir administration was preceded by a “lead-in” phase of 4 weeks with pegIFN/RBV alone in both trials. In the SPRINT-2 trial, the control group received placebo plus pegIFN/RBV for 44 weeks following the lead-in. The second group received boceprevir plus pegIFN/RBV for 24 weeks following the lead-in; those with detectable HCV RNA between Weeks 8 and 24 received placebo plus pegIFN/RBV through Week 48. In the final group, patients received boceprevir plus pegIFN/RBV 44 weeks following the lead-in.
Rates of SVR following treatment with boceprevir and pegIFN/RBV in treatment-naive (never before treated) patients were 67% and 68% in nonblack patients in the response-guided and 48-week arms, respectively, vs 40% in patients receiving pegIFN/RBV alone.
In black patients, the SVR rates were 42% and 53%, respectively, vs 23% in patients receiving pegIFN/RBV alone.
The treatment arms for the RESPOND-2 study were the same as for the SPRINT-2 study, except the response-guided arm received 32 weeks of pegIFN/RBV plus boceprevir following the lead-in phase, and patients with detectable HCV RNA at Week 8 received an additional 12 weeks of pegIFN/RBV through Week 48. In the RESPOND-2 study, SVR rates were 69% and 75% with response-guided and fixed-duration therapy in previous relapsers vs 29% following retreatment with pegIFN/RBV alone in this same population. Rates of SVR were 40% and 52%, respectively, for previous partial responders retreated with boceprevir plus pegIFN/RBV vs 7% for those retreated with pegIFN/RBV. In this trial, on-treatment response was an excellent predictor of SVR—rates of SVR were higher if patients had undetectable HCV RNA at Week 8, ie, Week 4 of boceprevir administration (86% and 88% after 32 and 44 weeks of triple therapy, respectively). "
"Because the genotype leading to better response is in substantially greater frequency in European than African populations, this genetic polymorphism also explains approximately half of the difference in response rates between African-Americans and patients of European ancestry."
This means if you take the IL28B test and your result is CC, your chances are actually better to SVR than a European who tests CT or TT.
Welcome and Good Luck.
Copyright 1994-2016 MedHelp International. All rights reserved.
MedHelp is a division of Aptus Health.
This site complies with the HONcode standard for trustworthy health information.
The Content on this Site is presented in a summary fashion, and is intended to be used for educational and entertainment purposes only. It is not intended to be and should not be interpreted as medical advice or a diagnosis of any health or fitness problem, condition or disease; or a recommendation for a specific test, doctor, care provider, procedure, treatment plan, product, or course of action. Med Help International, Inc. is not a medical or healthcare provider and your use of this Site does not create a doctor / patient relationship. We disclaim all responsibility for the professional qualifications and licensing of, and services provided by, any physician or other health providers posting on or otherwise referred to on this Site and/or any Third Party Site. Never disregard the medical advice of your physician or health professional, or delay in seeking such advice, because of something you read on this Site. We offer this Site AS IS and without any warranties. By using this Site you agree to the following Terms and Conditions. If you think you may have a medical emergency, call your physician or 911 immediately.